FDA approves first ever medication for obstructive sleep apnea — here's what that means
Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.
Future Market Insights6d
Global Continuous Positive Airway Pressure (CPAP) Market Poised for Sustained Growth, Reaching USD 900 Million by 2033 rise at a CAGR of 6%
The global continuous positive airway pressure (CPAP) market is projected to reach a value of USD 900 million by 2033, ...
The Gazette1d
This common disorder could be disrupting your sleep
Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.
Rolling Out4d
How a sleep mask for apnea reduces high blood pressure risk
Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...
The Washington Post on MSN12d
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
Too Old to Operate4d
Reduction in CPAP Use and Pneumothorax Rates in Infants in the Delivery Room
The following is a summary of “An Improvement Project to Lower Pneumothorax Rates in Neonates Born at 36 Weeks’ Gestational Age or Beyond,” published in the December 2024 issue of Pediatrics by ...
KSL4d
Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...
FDA approves first-ever medication for obstructive sleep apnea
“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...